A smart & precise approach with nanoparticles-based therapeutic intervention in neurodegenerative diseases

Document Type : Review Paper


1 Department of Biotechnology, Maulana Abul Kalam Azad University of Technology, West Bengal, NH 12, Haringhata, Post Office - Simhat, Haringhata, Pin - 741249 (Main Campus), India

2 Department of Life Sciences, RIMT University, Punjab, India


Neurodegenerative diseases (NDs) cause cell dysfunction with a gradual loss of neurons in the central nervous system and aberrant accumulation of aggregated proteins such as synuclein, tau, and amyloid. Alzheimer’s disease and Parkinson’s disease are the two frequently occurring neurodegenerative disorders. Nanobiotechnology being an emerging field used in applied biotechnology holds great potential for the advancement of treatments. This review aims to give a brief but comprehensive idea about the possibilities of utilizing the advanced nanotechnological aspect to treat the Alzheimer’s and Parkinson’s NDs that can be explored through proper investigations. In the present study, various kinds of literature were surveyed and reviewed to appreciate the neurodegenerative disease manifestation. It is becoming challenging to treat and discuss the potentiality of effective nano-mediated treatment strategies for Alzheimer’s and Parkinson’s diseases. The capability of current drugs to cross the blood-brain barrier (BBB) makes NDs’ treatment even more challenging. Recent therapies for such kinds of diseases are focused on symptomatic relief. Nanoparticulate drug delivery systems address all the challenges from all aspects and offer novel therapeutics for NDs. With targeted drug delivery of the required drug or protein to the site of interest, this approach is expected to turn out to be an exact and advanced therapeutic approach.


1. Masoudi Asil S, Ahlawat J, Guillama Barroso G, Narayan M. Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases. Biomater Sci. 2020;8(15):4109-4128. 
2. Kabanov A V, Howard Eliot Gendelman. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci. 2007;32(8-9):1054-1082. 
3. Kumar A, Kumar Chaudhary A, Singh R, Singh S, Wang Sh, Hoe Zh, et al. Nanotheranostic applications for detection and targeting neurodegenerative diseases. Front Neurosci. 2020;14:305. 
4. Neurodegenerative Disease. https://www.niehs.nih.gov/ research/supported/health/neurodegenerative/index. cfm. Accessed Date: 28/03/2021 5. Sim TM, Tarini D, Dheen ST, Bay BH, Srinivasan DK. Nanoparticlebased technology approaches to the management of neurological disorders. Int J Mol Sci. 2020;21(17): 6070. 
6. Patel HH. Is Alzheimer’s Disease Transmissible?. NewsMedical. 2021. 
7. Mandal A. Parkinson’s Disease Pathophysiology. NewsMedical. 2021. 
8. Tu Nguyen Kh, Nguyet Pham M, Van Vo T, Duan W, HaLien Tran Ph, Truong-Dinh Tran Th et al. Strategies of engineering nanoparticles for treating neurodegenerative disorders. Curr Drug Metab. 2017; 18(9):786-797. 
9. Poovaiah N, Davoudi Z, Peng H, Schlichtmann B, Mallapragada S, Narasimhan B et al. Treatment of neurodegenerative disorders through the blood-brain barrier using nanocarriers. Nanoscale. 2018;10(36):16962-16983.
10. Olivier Jean-Christophe. Drug transport to brain with targeted nanoparticles. NeuroRx. 2005;2(1):108–119. 
11. Armstrong J, Okun S. Diagnosis and treatment of parkinson disease a review. JAMA. 2020;323(6):548-560. 
12. Fornaguera C, Feiner-Gracia N, Calderó G, García-Celma MJ, Solans C. Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases. Nanoscale. 2015;7(28):12076-12084. 
13. Hernando S, Herran E, Pedraz JL, Igartua M, Hernandez RM. Nanotechnology based approaches for neurodegenerative disorders: Diagnosis and treatment. Drug and Gene Delivery to the Central Nervous System for Neuroprotection. 2017;57-87. 
14. Ram, Kamble Pavan, and Shaikh Karimunnisa Sameer. Effect of surfactants and co-surfactants on phase behaviour and physicochemical properties of self-nanoemulsifying drug delivery system loaded with plumbagin. Global J Pharm Sci. 2020;10:1-11. 
15. Geoffrey P, Soria FN, Thiolat ML, Daniel J, Verlhac JB, Blanchard-Desce M, Bezard E et al. Harnessing lysosomal pH through PLGA nanoemulsion as a treatment of lysosomal-related neurodegenerative diseases. Bioconjug Chem. 2018;29(12):4083-4089. 
16. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2008;127(2):97–109. 
17. Gobbi M, Re F, Canovi M, Beeg M, Gregori M, Sesana S, et al. Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials. 2010;31(25):6519-6529. 
18. Naz F, Siddique YH. Nanotechnology: Its application in treating neurodegenerative diseases. CNS & neurological disorders-drug targets (formerly current drug targets-cns & neurological disorders) 2021;20(1):34-53. 
19. Niu X, Chen J, Gao J. Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances. Asian J Pharm Sci. 2019; 14(5):480-496. 
20. Kaur G, Geeta A, Harikumar Sl. Nanosponge: New colloidal drug delivery system for topical delivery.  Indo-Glob Res J Pharm Sci. 2015;5(1): 53-57. 
21. Betzer O, Shilo M, Motei M, Popovtzer R. Insulin-coated gold nanoparticles as an effective approach for bypassing the blood-brain barrier. Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XVI. Vol. 10891. International Society for Optics and Photonics, 2019. 
22. Girigoswami A, Ramalakshmi M, Akhtar N, Metkar SK, Girigoswami K. ZnO Nanoflower petals mediated amyloid degradation-An in vitro electrokinetic potential approach. Mater Sci Eng C Mater Biol Appl. 2019; 101:169-178. 
23. Shilo M, Motiei M, Hana P, Popovtzer R. Transport of nanoparticles through the blood-brain barrier for imaging and therapeutic applications. Nanoscale. 2014; 6(4): 2146-2152. 
24. Aghaie T, Jazayeri MH, Manian M, Khani L, Erfani M, Rezayi M, et al. Gold nanoparticle and polyethylene glycol in neural regeneration in the treatment of neurodegenerative diseases. J Cell Biochem. 2019; 120(3 ):2749-2755. 
25. Ruff J, Hüwel S, Kogan MJ, Simon U, Galla HJ. The effects of gold nanoparticles functionalized with ß-amyloid specific peptides on an in vitro model of the blood-brain barrier. Nanomedicine.2017; 13(5):1645-1652. 
26. Hou K, Zhao J, Wang H, Li B, Li K, Shi X, et al. Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer’s disease. Nat Commun. 2020; 11(1):4790. 
27. Tang J, Xiong L, Zhou G, Wang S, Wang J, Liu L, et al. Silver nanoparticles crossing through and distribution in the blood-brain barrier in vitro. J Nano Sci Nanotechnol. 2010; 10(10):6313-6317. 
28. Huang CL, Hsiao IL, Lin HC, Wang CF, Huang YJ, Chuang CY. Silver nanoparticles affect on gene expression of inflammatory and neurodegenerative responses in mouse brain neural cells. Environ Res. 2015;136:253-263. 
29. Naz S, Beach J, Heckert B, Tummala T, Pashchenko O, Banerjee T, et al. Cerium oxide nanoparticles: A ‘radical’ approach to neurodegenerative disease treatment. Nanomedicine. 2017;12(5):545-553. 
30. Ron Hardman. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect. 2006;114(2):165-172. 
31. Barani M, Sabir F, Rahdar A, Kyzas G. Nanomaterials for the treatment and diagnosis of Alzheimer’s disease: An overview. NanoImpact. 2020;20:100251. 
32. Goldsmith M, Abramovitz L, Peer D. Precision nanomedicine in neurodegenerative diseases. ACS Nano. 2014;8(3):1958- 1965. 
33. Titova N, Chaudhuri KR. Ray Chaudhuri. Personalized medicine in Parkinson’s disease: time to be precise. Mov Disord. 2017;32(8):1147-1154. 
34. Payami H. The emerging science of precision medicine and pharmacogenomics for Parkinson’s disease. Mov Disord. 2017;32(8):1139-1146. 
35. Cascella R, Strafella C, Ragazzo M, Zampatti S, Borgiani P, Gambardella S, et al. Direct PCR: A new pharmacogenetic approach for the inexpensive testing of HLA-B* 57: 01. Pharmacogenomics J. 2015; 15(2):196-200. 
36. Strafella C, Caputo V, Galota MR, Zampatti S, Marella G, Mauriello S, et al. Application of precision medicine in neurodegenerative diseases. Fron Neurol. 2018;9:701. 
37. Kovacs GG, Milenkovic I, Wöhrer A, Höftberger R, Gelpi E, Haberler C, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: A community-based autopsy series. Acta Neuropathol. 2013; 126(3):365-384. 
38. Kovacs GG, Botond G, Budka H. Protein coding of neurodegenerative dementias: The neuropathological basis of biomarker diagnostics. Acta Neuropathol. 2010; 119(4):389-408. 
39. Kovacs, Gabor G. Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine. Int J Mol Sci. 2016;17(2):189. 
40. Breijyeh Z, Karaman R. Comprehensive review on alzheimer’s disease: Causes and Treatment. Molecules.2020;25(24):5789.
41. Shukla R Singh A, Handa M, Flora SJS, Kesharwani P. Nanotechnological approaches for targeting amyloid-b aggregation with potential for neurodegenerative disease therapy and diagnosis. Drug Discov Today. 2021;26(8):1972-1979.